Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Although in line with the Bank of England’s forecast for the headline rate to hit target by April, some signs remain troubling such as high services and core inflation, which both remain above 3 per ...

U.S. Rep. Byron Donalds believes there are ways to build artificial intelligence data centers in Florida without adverse ...

Federal Reserve governor Stephen Miran dialed back his calls for how deeply the Fed should cut rates this year, telling an ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

As work changes faster than org charts job architecture offers a shared language for workforce planning career paths and AI ...

As Federal Reserve chair, Kevin M. Warsh may face a tough task persuading his colleagues to lower borrowing costs because of ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

South Dakota legislative committees vetted nine data center bills on Wednesday at the Capitol, leaving three of the bills ...

SYDNEY, Feb 17 (Reuters) - Australia's central bank concluded inflation would stay stubbornly high if it had not hiked ...

Here’s how top analysts are interpreting the UK inflation landscape: ...